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Methods:
 
 Polymorphisms of the AGT, ACE (I/D) and AGTR1 (A1166C)
genes in patients and controls were analyzed using allele-specific PCR, and
PCR-rflp. 
 
Results: 
 
A total of 140 healthy subjects and 119 individuals with MI were
divided into two groups < 65 and > 65 years old. The evolution with age
showed that the AGT M allele (P < 0.001) and the ACE I allele (P < 0.05)
frequency decreased with age. The TT genotype frequency increased in
patients with MI > 65 years (OR =3.52; 95% CI; 3.12-5.54). The AA genotype
showed a similar behaviour (OR = 2.9; 95% CI; 1.11-5.6). The DD genotype
increased in the MI > 65 group (OR = 6.66; 95% CI; 2.02-21.9).  Serum ACE
activity was positively associated to age (r=0.38, p=0.000). Patients with DD
genotype > 65 years was significantly higher (119.7 ± 50.8 U/L) than in
patients with DD genotype < 65 years (96.9 ± 31.4 U/L, p=0.039).
 
Conclusions:
 
 The incidence of new cardiovascular disease continued to
increase after age 65 but was most often diagnosed at death. These findings
suggest that people aged 60 and older have a substantial amount of undiag-
nosed disease. We propose that the study of the allele frequency evolution in
an healthy population at different ages is essential to determine risk factors for
MI in case-control studies.
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Background:
 
 Arrhythmogenic right ventricular cardiomyopathy (ARVC)
is an inherited heart disease caused predominantly by heterozygous Plako-
philin-2 (PKP2) mutations. However, few molecular studies have been per-
formed to ascertain their pathogenicity. PKP2 encodes two isoforms, the
longest (PKP2b) including the alternatively spliced exon 6, which is routinely
screened for molecular diagnosis, despite the absence of data on the cardiac
expression of PKP2 isoforms. This study addressed the pathogenicity of exon
6 mutations by focusing on a heterozygous missense p.Arg490Trp variant in
PKP2. 
 
Methods and results:
 
 The p.Arg490Trp variant of PKP2 was identified in two
unrelated ARVC probands and absent from 470 controls. In silico analysis sug-
gests that PKP2 exon 6 is an Alu-derived sequence with very low expression level.
Transcriptional and Western blot analysis confirmed that the exon 6 missing
PKP2a was the only clearly detectable isoform in all heart samples (four controls
and a proband). Moreover, in the proband's heart sample, the variant was not asso-
ciated with aberrant exon 6 splicing or mutant mRNA down-regulation. Finally,
we identified in this proband a heterozygous missense variant (p.Glu2343Lys) in
the desmoplakin gene likely to be the disease-causing mutation.
 
Conclusion:
 
 We demonstrated that only PKP2a is significantly expressed in
the heart. Our results strongly suggest that the p.Arg490Trp mutation and other
variants located in PKP2 exon 6 can not be considered as disease-causing muta-
tions and therefore that PKP2 exon 6 screening is useless in routine ARVC
molecular diagnosis. These results have important consequences for the interpre-
tation of PKP2 mutation screening and subsequent genetic counseling.
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Aim:
 
 A major risk of myocardial ischemia (MI) is the onset of ventricular
fibrillation (VF). Our study evaluated the effect of heart rate reduction (HRR)
induce by ivabradine (IVA), the first selective inhibitor of the pacemaker cur-
rent If, on the risk of onset of VF, and study the possible mechanisms
involved.
 
Methods:
 
 MI was induced in pigs by total occlusion of the anterior inter-
ventricular artery until onset of VF, which was assessed by the VF threshold
(VFT; protocol 1) or the time to onset of VF (TOF; protocol 2), with or
without IVA (0.25mg/kg, i.v.). Electrophysiological, 
hemodynamic parameters and ischemic area were assessed in these two proto-
cols. The impact of IVA was evaluated on: i) ultrastructure of mitochondria
(by electron microscopy) in protocol 1; ii) myocardial energetic status com-
pared with a ß-blocker, propranolol (PROP) in protocol 2; iii) regional myo-
cardial blood flow (RMBF) after 1 min-ischemia followed (without VF) by
reperfusion by positrons emission tomography in protocol 3. 
 
Results:
 
 IVA induced a significant HRR (~25%), increased the VFT and
the TOF. When compare to control, IVA prevented the apparition of mito-
chondrial alterations due to repetitive sequences of MI/VF and reperfusion.
IVA improved the RMBF during reperfusion (after 1 min-occlusion). Also, the
myocardial energetic status evaluated by the concentrations of high energy
phosphates, was in part preserved with IVA. All of these changes were corre-
lated with IVA-induced HRR and were not associated with modifications in
the dP/dtmax.
 
Conclusions:
 
 Our results showed that IVA decreases the risk of the onset
of ischemia-induced VF. This effect can be explained by a preservation of
ultrastructure of mitochondria, an improvement in the RMBF and a better con-
servation of myocardial energetic status. Although further work is needed to
determine the mechanisms underlying these effects, this might give a place of
choice to IVA in the prevention of ischemia-induced VF.
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Aim: 
 
The spontaneously hypertensive rat (SHR) is a model of hypertension
with a Cd36 gene defect, which develops left ventricular hypertrophy (LVH)
between 9 and 12 weeks. At 15 weeks, perfused SHR hearts display a reduced
capacity to use long chain fatty acids (LCFAs) but not carbohydrates (CHOs)
for energy production. In this study, we have further examined LCFA metab-
olism and its potential (dys)regulation in SHR hearts prior to LVH. 
 
Methods:
 
 SHR and control Wistar rat hearts (7 weeks) have been used for:
i) functional and metabolic phenotyping using 
 
ex vivo
 
 perfusion with 
 
13
 
C-
labeled substrates, ii) metabolic gene expression profiling using qPCR, iii)
studies of mechanisms regulating -oxydation (malonyl-CoA, AMPK) and of
the functional impact of the gene mutation in the LCFA transporter Cd36
(western blot, confocal microscopy, qPCR, gene analysis).
 
Results:
 
 Compared to controls, 7-week-old SHR hearts display a lower
contribution of LCFA (i.e. oleate) to oxidation (40%) and triglyceride (2.8-
fold) formation, which is associated with a compensatory increase in CHO
oxidation. These alterations cannot be explained by changes in metabolic gene
expression or common mechanisms regulating -oxidation. Western analyses
demonstrate that compared to controls, cardiac CD36 protein level is lower in
the SHR, while data from confocal microscopy indicate a similar intracellular
localization. Sequence alignment of Cd36 cDNA indicates non-synonymous
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mutations in the SHR that do not impact on the molecular weight of the native
protein, but may affect its post-translational modification (PTM). This notion
is supported by additional data, which suggest an alteration in 
 
O
 
-linked -N-
acetylglucosamination. 
 
Conclusion:
 
 Our results emphasize the role of the SHR Cd36 gene defect
as the factor underlying its cardiac restricted LCFA utilization. The functional
impact of this gene defect includes alterations in CD36 protein level and sus-
ceptibility to PTM.
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Introduction:
 
 Thrombi in contact with non re-endothelialized stent struts
associated with drug-eluting stent (DES) thrombosis. Hence, detection of
thrombi in DES could help to evaluate the risk of DES thrombosis. Annexin
V radio-labelled with 99mTechnetium (99mTc) is a radio-tracer with a high
affinity for activated platelets.
 
Objectives:
 
 Our objectives were: 1) to develop an animal model of non-
occlusive thrombosis of stents, 2) to evaluate the ability of annexin V 99mTc
for the detection of in-stent thrombi using scintigraphy. 
 
Methods:
 
 Right carotid arteries of NZW rabbits (n = 14) fed a high cho-
lesterol diet were implanted with overlapping DES (n = 7) or bare-metal
stents (BMS; n = 7). Four weeks after stent implantation, rabbits underwent
a first scintigraphy 3 hours after injection of 200 MBq of radio-labelled
annexin V 99mTc. At the end of the first scintigraphy, a suture was placed
surgically proximal to the stented carotid arteries in order to induce a
thrombus-prone flow limiting stenosis. Four days later, a second scintig-
raphy was performed. After the second scintigraphy, stents were excised,
imaged ex vivo and then fixed for histological examination and scanning
electron microscopy (SEM). 
 
Results:
 
 Activities measured in vivo in the stented carotid arteries after injec-
tion of annexin V 99mTc were higher on the second scintigraphy after creation
of a surgical stenosis as compared to the first scintigraphy (0.24 vs. 0.15 counts/
pixel/ MBq, respectively; p<0.05). On the second scintigraphy, activities were
higher in DES vs. BMS (0.26 vs. 0.19 counts/pixel/ MBq, respectively;
p < 0.005). High activities measured in stents in vivo were associated with the
detection of thrombi on corresponding histological sections and SEM.
 
Conclusions:
 
 In this work, we developed a rabbit model of non-occlusive
thrombosis of stents in carotid arteries. In this model, in-stent thrombi could
be detected using annexin V 99mTc scintigraphy.
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Aim: Glutamine is the most abundant amino acid in the plasma, and has
been shown to exert cardioprotective effects. However, the underlying mech-
anisms remained unclear, but may include an anaplerotic effect via its meta-
bolic conversion to citric acid cycle (CAC) intermediates or activation of the
hexosamine biosynthetic pathway (HBP). 
Methods: To assess the potential roles of these mechanisms, we evaluated
the metabolic effects of a physiologically relevant concentration of glutamine
(0.5mM) in isolated working rat hearts perfused with 13C-labeled substrates
with or without 20 M azaserine (an HBP inhibitor) and under restricted supply
of carbohydrates (CHO, i.e. without pyruvate/insulin). 
Results: When perfused with a mixture of CHOs, a fatty acid oleate and
insulin (controls), the addition of glutamine had no effect on functional
parameters except for a 17% (p<0.05) decrease in relaxation. However it
resulted in an increase in the percent contribution of 13C-oleate to acetyl-
CoA production (51%) and triglyceride formation (2.8 folds). This was
accompanied by a significant reduction (p>0.05) tissue levels of the CAC
intermediates (in nmol/gww): citrate: 260±10 vs. 222±6 and malate 128±5
vs. 103±3 . Inhibition of HBP with azaserine restored oleate oxidation and
tissue CAC levels, but not triglyceride formation. When perfused under
restricted supply of CHOs, hearts displayed significantly decreased cardiac
output (65%), a greater percent contribution of glucose to pyruvate forma-
tion (60%), and lower tissue citrate and malate levels (45%). Addition of
glutamine restored cardiac output and glucose contribution to pyruvate for-
mation but not tissue CAC levels. 
Conclusion: Collectively, these results demonstrate the capacity of
glutamine to modulate energy substrate selection and function in the perfused
heart. Furthermore, the potential mechanisms underlying these effects appear
to be mediated via the HBP rather than anaplerosis.
257
Prevalence of aspirin resistance in stable coronary heart diseased
patients and correlation with platelet turn-over.
Thibaut Petroni (1), Sebastian Voicu (2), Bernadette Boval (3), Georges
Sideris (2), Jean-Guillaume Dillinger (2), Claire Bal Dit Sollier (3), Ludo-
vic Drouet (3), Patrick Henry (2)
(1) CHU Pitié Salpêtrière, Institut de cardiologie, Service de Réanimation
Médicale, Paris, France - (2) CHU Lariboisière, Département de Cardio-
logie, Paris, France - (3) CHU Lariboisière, Service d'Hématologie-
Hémostase, Paris, France
Background: Aspirin resistance has been widely reported but the under-
lying mechanisms remain unclear. Previous studies have suggested a relation-
ship between accelerated platelet turn-over and aspirin resistance in patients
with coronary artery disease. The purpose of this study was to determine
whether aspirin resistance could be linked to accelerated platetet turn-over.
Methods: We performed a prospective monocentric study including 50
consecutive patients with stable coronary artery disease treated by aspirin (75
to 250 mg/day) without any other antiaggregant treatment. Aspirin resistance
was characterized 24 hours after aspirin intake by light transmission aggrego-
metry using 0.5 mg/mL arachidonic acid. Aspirin resistance was defined as
>20% residual agregation. Platelet turn-over was estimated at the same time
by measurement of mean platelet volume, % of reticulated platelets, serum P-
selectin, platelet P-selectin and serum thrombopoietin.
Results: Among 50 patients (70±11 y.o. mean±1,5, 76% male, 52% type 2
diabetes mellitus, 16% active smokers), 18 (36%) were identified as aspirin
resistants. Table 1 shows the mean value of markers currently linked to
platelet turn-over depending on the presence of aspirin resistance. Serum
thrombopoietin was significantly increased in patients with aspirin resistance
compared to patients with no aspirin resistance. No statistical difference was
demonstrated for mean platelet volume, reticulated platelets, platelet P-selectin
and serum P-selectin. Serum thrombopoietin values were not correlated with
other platelet turn-over parameters. There was no significant correlation
between serum thrombopoietin and inflammatory markers.
Conclusion: Serum thrombopoietin is associated with aspirin resistance,
but no other parameters currently linked to platelet turn-over. Further studies
are needed to determine whether serum thrombopoietin can predict aspirin
resistance in a larger cohort.
